Andre behandlingsrelaterede bivirkninger, som forekom hos ≥1% af patienterne i det pivotale forsøg, omfatter hypokaliæmi (3, 1%), diarré (3, 1%), stigning i ALAT (2, 3%), stigning i leverenzymer (1, 5%), stigning i serum- alkalisk fosfatase (1, 5%) og stigning i serum- bilirubin (1, 5%).
Other treatment-related adverse reactions that occurred in ≥ 1% of patients in the pivotal study included hypokalemia (3.1%), diarrhoea (3.1%), ALT increased (2.3%), hepatic enzyme increased (1.5%), blood alkaline phosphatase increased (1.5%), and blood bilirubin increased (1.5%).